Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sagimet Biosciences Inc. (SGMT : NSDQ)

• Company Description    Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $10.71 Daily Weekly Monthly 20 Day Moving Average: 1,117,301 shares Shares Outstanding: 62.16 (millions) Market Capitalization: $665.72 (millions) Beta: 3.45 52 Week High: $11.27 52 Week Low: $4.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.50% 13.30% 12 Week 70.00% 66.41% Year To Date 80.91% 61.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 950 Tower Lane Suite 1500 - Foster City,CA 94404 USA ph: 650-561-8600 fax: - ir@sagimet.com http://www.sagimet.com

• General Corporate Information    Officers David Happel - President and Chief Executive Officer George Kemble - Chairman Thierry Chauche - Chief Financial Officer Anne Phillips - Director Beth Seidenberg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 786700104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 62.16 Most Recent Split Date: (:1) Beta: 3.45 Market Capitalization: $665.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.75% vs. Previous Quarter: 21.21% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -31.96 03/31/26 - -37.57 12/31/25 - -40.85 ROA 06/30/26 - -30.57 03/31/26 - -35.52 12/31/25 - -38.63 Current Ratio 06/30/26 - 45.03 03/31/26 - 20.33 12/31/25 - 22.82 Quick Ratio 06/30/26 - 45.02 03/31/26 - 20.34 12/31/25 - 22.82 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 4.15 03/31/26 - 3.14 12/31/25 - 3.42 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©